XML 99 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity Investments (Details)
1 Months Ended 12 Months Ended
Aug. 15, 2024
USD ($)
Feb. 07, 2023
$ / shares
shares
Apr. 30, 2024
USD ($)
shares
Apr. 30, 2022
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
May 31, 2021
USD ($)
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt and Equity Securities, FV-NI [Line Items]                  
Mark-to-market gain (loss)             $ 5,683,000 $ 53,461,000 $ (18,084,000)
Cash payments to purchase of shares             3,072,000 4,125,000 600,000
Nimbus Therapeutics, LLC                  
Debt and Equity Securities, FV-NI [Line Items]                  
Non-marketable equity security             2,436,000 1,928,000  
Unrealized (loss) gain             508,000 1,928,000 0
Realized gain               147,213,000  
Morphic Holding, Inc.                  
Debt and Equity Securities, FV-NI [Line Items]                  
Proceeds from sale of equity securities $ 47,588,000                
Mark-to-market gain (loss)             23,474,000 1,778,000 (17,226,000)
Marketable securities             0 24,114,000  
Ajax Therapeutics, Inc                  
Debt and Equity Securities, FV-NI [Line Items]                  
Non-marketable equity security             4,498,000 1,700,000  
Mark-to-market gain (loss)             (202,000) 0 0
Structure Therapeutics                  
Debt and Equity Securities, FV-NI [Line Items]                  
Mark-to-market gain (loss)             (18,096,000) 49,755,000 $ (858,000)
Marketable securities             $ 36,202,000 $ 55,509,000  
Series B preferred stock | Structure Therapeutics                  
Debt and Equity Securities, FV-NI [Line Items]                  
Number of preferred shares purchased | shares       148,210 494,035        
Cash payments to purchase of shares       $ 600,000 $ 2,000,000        
Conversion ratio   1              
Series B preferred stock | Ajax Therapeutics, Inc                  
Debt and Equity Securities, FV-NI [Line Items]                  
Number of preferred shares purchased | shares           631,377      
Cash payments to purchase of shares           $ 1,700,000      
ADR | Structure Therapeutics                  
Debt and Equity Securities, FV-NI [Line Items]                  
Number of shares purchased | shares   275,000              
Purchase price (in USD per share) | $ / shares   $ 15.00              
Stock split, conversion ratio   3              
Series C preferred stock | Ajax Therapeutics, Inc                  
Debt and Equity Securities, FV-NI [Line Items]                  
Number of preferred shares purchased | shares     1,416,450            
Cash payments to purchase of shares     $ 3,000,000